 |
|
Prostate Cancer in a Transgender Woman 41 Years After Initiation of Feminization
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: The development of prostate cancer after orchiectomy is rare. In transgender women, the longest duration between initiation of estrogen therapy and diagnosis previously reported was 12 years.1-2 We report a case of a male-to-female transgender woman with locally advanced prostate cancer diagnosed 41 years after feminization.
Report of a Case
In May 2005, a 60-year-old transgender woman presented with gross hematuria. She had started feminizing estrogen therapy at 19 years of age. After 5 years of weekly estrogen injections (details unknown), she used conjugated estrogen tablets (Premarin, 2.5 mg daily) until bilateral orchiectomy at age 34 years. Thereafter, she took conjugated estrogen tablets (Premarin, 1.25 mg daily) except between the ages of 50 and 56 years, when she took no estrogen because of acquisition difficulties. Family history was negative for prostate cancer.
A large anterior mass was palpated on digital neovaginal examination. Her serum prostate-specific antigen (PSA) level was 240 ng/mL; . . . [Full Text of this Article]
Rebecca A. Miksad, MD
Rebecca_Miksad@post.harvard.edu
Glenn Bubley, MD
Division of Hematology and Oncology
Paul Church, MD;
Martin Sanda, MD
Division of Urology
Neil Rofsky, MD
Department of Radiology
Irving Kaplan, MD
Department of Radiation Oncology
Beth Israel Deaconess Medical Center
Boston, Mass
Amiel Cooper, MD
Department of Pathology
Faulkner Hospital
Boston, Mass
|
